New hope for tough lymphomas: experimental drug MDX2003 enters human testing

NCT ID NCT07249905

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called MDX2003 in 180 adults with B-cell lymphomas (like diffuse large B-cell lymphoma or follicular lymphoma) that have returned or stopped responding to at least two prior treatments. The main goals are to find the safest dose and check if the drug can shrink tumors. Participants will be closely monitored for side effects and treatment response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma high grade B-cell lymphoma interdigitating dendritic cell sarcoma lymphoma Lymphoma, B-Cell, Marginal Zone lymphoplasmacytic lymphoma mantle cell lymphoma marginal zone lymphoma primary mediastinal large B-cell lymphoma Richter transformation Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Epworth HealthCare

    RECRUITING

    Richmond, Victoria, 3121, Australia

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Linear Clinical Research

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••